U.S. Markets open in 1 hr 49 mins
  • S&P Futures

    3,421.50
    -30.25 (-0.88%)
     
  • Dow Futures

    27,923.00
    -266.00 (-0.94%)
     
  • Nasdaq Futures

    11,581.75
    -81.75 (-0.70%)
     
  • Russell 2000 Futures

    1,615.80
    -19.80 (-1.21%)
     
  • Crude Oil

    38.99
    -0.86 (-2.16%)
     
  • Gold

    1,905.80
    +0.60 (+0.03%)
     
  • Silver

    24.38
    -0.30 (-1.22%)
     
  • EUR/USD

    1.1830
    -0.0038 (-0.3194%)
     
  • 10-Yr Bond

    0.8410
    0.0000 (0.00%)
     
  • Vix

    29.70
    +1.59 (+5.66%)
     
  • GBP/USD

    1.3060
    +0.0022 (+0.1672%)
     
  • USD/JPY

    104.8590
    +0.1690 (+0.1614%)
     
  • BTC-USD

    13,139.96
    +62.94 (+0.48%)
     
  • CMC Crypto 200

    263.79
    +2.34 (+0.89%)
     
  • FTSE 100

    5,852.27
    -8.01 (-0.14%)
     
  • Nikkei 225

    23,494.34
    -22.25 (-0.09%)
     

Allergy Therapeutics (LON:AGY) Share Prices Have Dropped 51% In The Last Three Years

Simply Wall St
·3 mins read

Allergy Therapeutics plc (LON:AGY) shareholders should be happy to see the share price up 16% in the last quarter. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 51% in the last three years. Some might say the recent bounce is to be expected after such a bad drop. After all, could be that the fall was overdone.

View our latest analysis for Allergy Therapeutics

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During five years of share price growth, Allergy Therapeutics moved from a loss to profitability. That would generally be considered a positive, so we are surprised to see the share price is down. So given the share price is down it's worth checking some other metrics too.

We note that, in three years, revenue has actually grown at a 7.2% annual rate, so that doesn't seem to be a reason to sell shares. This analysis is just perfunctory, but it might be worth researching Allergy Therapeutics more closely, as sometimes stocks fall unfairly. This could present an opportunity.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

We know that Allergy Therapeutics has improved its bottom line over the last three years, but what does the future have in store? It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

We're pleased to report that Allergy Therapeutics shareholders have received a total shareholder return of 26% over one year. That certainly beats the loss of about 6.9% per year over the last half decade. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Allergy Therapeutics (1 is concerning!) that you should be aware of before investing here.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on GB exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.